- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jewel Mullen Discusses NASEM's Framework for an Equitable Distribution of a COVID-19 Vaccine
Recently released vaccine data indicate encouraging steps forward in the global fight against coronavirus disease 2019 (COVID-19). When vaccine doses first become available, who should be prioritized?
Recently released vaccine data from Pfizer, Moderna, and AstraZeneca indicate encouraging steps forward in the global fight against coronavirus disease 2019 (COVID-19). But all 3 vaccines are still a long way from becoming readily available to the wider public, prompting the question, who should be prioritized once doses become available?
To provide guidance on this front, the National Institutes of Health (NIH) and CDC requested The National Academies of Science, Engineering, and Medicine (NASEM) to construct a framework assisting US policy makers and global health communities to plan for an equitable allocation of a COVID-19 vaccine.
On this episode of Managed Care Cast, we speak with Jewel Mullen, MD, MPH, the associate dean for health equity and associate professor of population health and internal medicine at the University of Texas at Austin, Dell Medical School. Mullen is the former principal deputy assistant secretary for health in HHS and a member of the National Academies committee which developed the framework for vaccine allocation.
Mullen discusses criteria used to prioritize vaccine recipients, barriers to equitable distribution, and the role of misinformation in the push for an effective COVID-19 vaccine.
Listen above or through one of these podcast services:
Read more:
Pfizer Says Vaccine 90% Effective; Biden Team Announces COVID-19 Transition Panel
Study Backs Decision to Move Forward With Pfizer Vaccine Candidate
Moderna SARS-CoV-2 Vaccine Elicits Response in Older Adults
Dr Maura Abbott: Talk to Your Patients About Their Vaccine Fears
Dr Maura Abbott: COVID-19 Vaccine Development Process Is Safe Despite a Quicker Timeline
Dr Victoria Smith on Experience Taking Part in a COVID-19 Vaccine Trial
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
